0001354488-15-004828.txt : 20151109 0001354488-15-004828.hdr.sgml : 20151109 20151105140015 ACCESSION NUMBER: 0001354488-15-004828 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20151102 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151105 DATE AS OF CHANGE: 20151105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WOUND MANAGEMENT TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0000714256 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 592220004 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11808 FILM NUMBER: 151199909 BUSINESS ADDRESS: STREET 1: 777 MAIN STREET STREET 2: SUITE 3100 CITY: FORT WORTH STATE: TX ZIP: 76102 BUSINESS PHONE: 817-820-7080 MAIL ADDRESS: STREET 1: 777 MAIN STREET STREET 2: SUITE 3100 CITY: FORT WORTH STATE: TX ZIP: 76102 FORMER COMPANY: FORMER CONFORMED NAME: MB SOFTWARE CORP DATE OF NAME CHANGE: 19960805 FORMER COMPANY: FORMER CONFORMED NAME: INAV TRAVEL CORPORATION DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TWISTEE TREAT CORP DATE OF NAME CHANGE: 19910220 8-K 1 wndm_8k.htm CURRENT REPORT wndm_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 2, 2015

Wound Management Technologies, Inc.
(Exact name of registrant as specified in its charter)
 
Texas
000-11808
59-2219994
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
16633 Dallas Parkway, Suite 250
Addison, Texas
   75001
(Address of principal executive offices)  
(zip code)
 
Registrant’s telephone number, including area code: (972) 218-0935
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 2, 2015, Robert H. Lutz, Jr. gave notice to Wound Management Technologies, Inc. (the “Company”) that he would be resigning from his positions as a member and chairman of the Board of Directors, as well as his position as Chief Executive Officer of the Company. Mr. Lutz, 66, is retiring, and did not resign as the result of any disagreement with the Company.
 
Item 9.01.  Financial Statements and Exhibits
 
(d) Exhibits.
 
Exhibit No.   Description
     
17.1   Resignation Letter of Robert H. Lutz, Jr., dated November 5, 2015
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Wound Management Technologies, Inc.  
       
Date: November 5, 2015
By:
/s/ Darren Stine, Chief Financial Officer  
    Darren Stine  
    Chief Financial Officer  
       
 
 
 
 
3
EX-17.1 2 wndm_ex171.htm RESIGNATION LETTER wndm_ex171.htm
EX. 17.1
 
Resignation Letter of Robert H. Lutz, Jr.

To the Board of Directors:

As discussed during our September meeting in Dallas, it is time for me to proceed with the announcement of my retirement. Consequently, I submit my resignation as Chairman and CEO  effective December 1, 2015. I am confident in the management team’s ability to execute our plan resulting in continued revenue growth from both our CellerateRX and bone wax product lines. I have never been more confident in the opportunity before the company.

It has been a pleasure to be associated with the company and each of you and I will continue to offer my support to further the success of the company.

Best regards.

Robert Lutz, Jr.